The Massachusetts General Hospital has long been a pioneer in the development and application of PET technology to problems of biomedical importance. The MGH PET imaging program is actively supported by NIH-funded research addressing questions of fundamental importance in fields such as experimental pharmacology, tumor biology, molecular imaging, and cognitive neuroscience. The MGH PET imaging effort has had great success in translating recent scientific developments from the bench to the bedside. The use of PET imaging to address specific patient-related clinical questions has risen dramatically, especially in the areas of oncology, neurology, and cardiology. As a result of growing awareness about the clinical impact of using PET to promote patient care, clinical demands on the existing MGH PET facility on the hospital campus are escalating;this facility has limited growth potential for research activity, given both increasing demands for clinical use and the age of the equipment. Already overburdened, the facility cannot keep pace with growing research demands of the scope necessary to advance PET development-and possible with dedicated research facilities at the research campus. Initially, the research-dedicated PET imaging facility in Charlestown will have two imaging devices located at the Martinos Center: a first-of-its-kind combined PET-MR imaging system installed in early 2008, and a Concord microPET system for animal imaging that is currently operating in a temporary laboratory on the main campus and will be transferred to the Charlestown facility once the cyclotron and other essential radiopharmaceutical resources are up and working. Plans call for additional imaging instruments to be added as the program grows. The proposed C-11 synthesizer will be a critical component of the new PET facility's capabilities to synthesize radioligands for ongoing and planned research projects. Given the exceptional biomedical imaging research community co-located at the MGH research campus, the broad multimodality imaging resources of the Martinos Center, the critically overburdened state of the existing MGH clinical campus PET facilities, and the existing technical expertise and infrastructure in place, the proposed C-11 radiopharmaceutical production system will immediately increase the efficiency, accessibility, and innovation of existing research, and play a critical role in completing the MGH's strategy to provide an integrated biomedical imaging research environment that includes PET imaging. The proposed C-11 radiopharmaceutical production system has the highest performance of the commercial systems currently available for production C-11 labeled radiopharmaceuticals. The synthesizer must balance a number of factors in the design to fulfill requirements for performance, accessibility and fitness to the research environment. PUBLIC HELATH
In compliance with FDA cGMP guidelines and USP 797, we propose to establish carbon-11 radiopharmaceutical production. Given the exceptional biomedical imaging research community co-located at the MGH research campus, the broad multi-modality imaging resources of the Martinos Center, the critically overburdened state of the existing MGH clinical campus PET facilities, and the existing technical expertise and infrastructure in place, the proposed C-11 radiopharmaceutical production system has the potential to immediately increase the efficiency, accessibility, and innovation of research programs at the institution, and complete the MGH's strategy to provide an integrated biomedical imaging research environment.
| Van de Bittner, Genevieve C; Van de Bittner, Kyle C; Wey, Hsiao-Ying et al. (2018) Positron Emission Tomography Assessment of the Intranasal Delivery Route for Orexin A. ACS Chem Neurosci 9:358-368 |
| Schoenberger, Matthias; Schroeder, Frederick A; Placzek, Michael S et al. (2018) In Vivo [18F]GE-179 Brain Signal Does Not Show NMDA-Specific Modulation with Drug Challenges in Rodents and Nonhuman Primates. ACS Chem Neurosci 9:298-305 |
| Van de Bittner, Genevieve C; Riley, Misha M; Cao, Luxiang et al. (2017) Nasal neuron PET imaging quantifies neuron generation and degeneration. J Clin Invest 127:681-694 |
| Hooker, Jacob M; Strebl, Martin G; Schroeder, Frederick A et al. (2017) Imaging cardiac SCN5A using the novel F-18 radiotracer radiocaine. Sci Rep 7:42136 |
| Wang, Changning; Schroeder, Frederick A; Hooker, Jacob M (2017) Development of New Positron Emission Tomography Radiotracer for BET Imaging. ACS Chem Neurosci 8:17-21 |
| Sander, Christin Y; Mandeville, Joseph B; Wey, Hsiao-Ying et al. (2017) Effects of flow changes on radiotracer binding: Simultaneous measurement of neuroreceptor binding and cerebral blood flow modulation. J Cereb Blood Flow Metab :271678X17725418 |
| Hansen, Hanne D; Mandeville, Joseph B; Sander, Christin Y et al. (2017) Functional Characterization of 5-HT1B Receptor Drugs in Nonhuman Primates Using Simultaneous PET-MR. J Neurosci 37:10671-10678 |
| Sander, Christin Y; Hesse, Swen (2017) News and views on in-vivo imaging of neurotransmission using PET and MRI. Q J Nucl Med Mol Imaging 61:414-428 |
| Sander, Christin Y; Hooker, Jacob M; Catana, Ciprian et al. (2016) Imaging Agonist-Induced D2/D3 Receptor Desensitization and Internalization In Vivo with PET/fMRI. Neuropsychopharmacology 41:1427-36 |
| Strebl, Martin G; Wang, Changning; Schroeder, Frederick A et al. (2016) Development of a Fluorinated Class-I HDAC Radiotracer Reveals Key Chemical Determinants of Brain Penetrance. ACS Chem Neurosci 7:528-33 |
Showing the most recent 10 out of 46 publications
